000504.SHE Nanhua Bio Medicine Co Ltd
- Market cap
- CNY 2.61B
- P/E
- 113.0x
- P/B
- 9.73x
- ROE
- -1.1%
- Dividend yield
- 0.09%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000504.SHE undervalued?
Graham numberThe Graham number of Nanhua Bio Medicine Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nanhua Bio Medicine Co Ltd fundamental analysis
No fundamental analysis for Nanhua Bio Medicine Co Ltd yet.
Nanhua Bio Medicine Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nanhua Bio Medicine Co Ltd
Landfar Bio-medicine Co., Ltd operates as a biomedical technology company. It operates in two segments, Biomedicine, and Energy Saving and Environmental Protection. The Biomedicine segment provides stem cell and immune cell testing, storage, and technical services; as well as sales of biopharmaceutical products, such as beauty products, health supplements, and air purifiers. The Energy Saving and Environmental Protection segment is involved in the external energy management …
Full company profileNanhua Bio Medicine Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nanhua Bio Medicine Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 67.3M | 67.4M | 95.4M | 134M | 176M | 157M | 200M | 137M | 134M | 416M | 555M |
| Gross Profit | 21.7M | 17.2M | 60.2M | 80.4M | 95.8M | 110M | 127M | 91.9M | 89.7M | 91.8M | 38.4M |
| Operating Income | 20.7M | -35.8M | -34.7M | 16.6M | 18.9M | -30.7M | -26.1M | -45.7M | -20.8M | 30.9M | -13.7M |
| EBITDA | 39.7M | -24.4M | -20.2M | 32.0M | 26.3M | -10.3M | -5.27M | -30.6M | -16.5M | 29.1M | -15.5M |
| Net Income | 21.8M | -37.1M | -35.2M | 18.8M | 8.15M | -19.1M | -12.5M | -28.2M | -19.8M | 28.8M | -3.00M |
| EPS | 0.07 | -0.12 | -0.11 | 0.06 | 0.03 | -0.06 | -0.04 | -0.09 | -0.06 | 0.09 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 301M | 405M | 343M | 268M | 556M | 659M | 553M | 771M | 608M | 992M | 815M |
| Total Liabilities | 221M | 276M | 235M | 154M | 422M | 549M | 473M | 467M | 326M | 634M | 471M |
| Shareholders' Equity | 5.27M | 24.6M | -10.3M | 18.4M | 26.6M | 16.6M | 13.8M | 257M | 237M | 266M | 264M |
| Cash & Short-term Investments | 98.1M | 168M | 60.1M | 70.4M | 67.7M | 154M | 220M | 496M | 208M | 347M | 310M |
| Total Debt | 136M | 160M | 89.0M | 50.1M | 13.0M | 52.1M | 80.7M | 44.3M | 24.1M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -14.6M | -47.4M | -15.2M | 14.5M | -207M | 107M | 166M | 36.3M | 4.79M | -116M | - |
| Capital Expenditure | 4.26M | 1.03M | 9.30M | 2.57M | 4.47M | 32.0M | 16.9M | 5.92M | 18.3M | 5.12M | 10.3M |
| Free Cash Flow | -18.9M | -48.4M | -24.5M | 11.9M | -212M | 75.1M | 149M | 30.4M | -13.5M | -121M | -5.32M |
| Ratios | |||||||||||
| ROE | 412.6% | -150.6% | - | 102.1% | 30.7% | -114.9% | -90.5% | -11.0% | -8.4% | 10.8% | -1.1% |
| ROA | 7.2% | -9.2% | -10.3% | 7.0% | 1.5% | -2.9% | -2.3% | -3.7% | -3.3% | 2.9% | -0.4% |
| Net Profit Margin | 32.4% | -55.1% | -36.9% | 14.0% | 4.6% | -12.2% | -6.2% | -20.6% | -14.8% | 6.9% | -0.5% |
| Debt to Equity | 25.72x | 6.49x | - | 2.72x | 0.49x | 3.13x | 5.86x | 0.17x | 0.10x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nanhua Bio Medicine Co Ltd dividends
- Dividend yield
- 0.09%
- Forward dividend
- -
- Payout ratio
- 8.2%
- Ex-dividend date
- Apr 23, 2004
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 2.37M | 0.01 | 8.2% |
| 2024 | CNY 931K | 0.00 | - |
| 2023 | CNY 2.29M | 0.01 | - |
| 2022 | CNY 2.40M | 0.01 | - |
| 2021 | CNY 2.12M | 0.01 | - |
| 2020 | CNY 1.12M | 0.00 | 13.8% |
| 2019 | CNY 12.4M | 0.04 | 66.0% |
| 2018 | CNY 9.13M | 0.03 | - |
| 2017 | CNY 8.79M | 0.03 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 13:10 on Jan 15, 2007.
Who owns Nanhua Bio Medicine Co Ltd
- Insiders 8.72%
- Institutions 40.60%
- Public & others 50.68%
- Shares outstanding 330M
- Free float 225M
Nanhua Bio Medicine Co Ltd company profile
- Company name
- Nanhua Bio Medicine Co Ltd
- Ticker
- 000504.SHE
- ISIN
- CNE000000263
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Oct 28, 1991
- Sector
- Healthcare
- Industry
- Media
- Employees
- 316
- Fiscal year end
- December
- Address
- Lugu Science and Technology, Changsha, China, 410205
- Phone
- 86 73 1858 10285
- Website
- landfar.cn
About Nanhua Bio Medicine Co Ltd
Landfar Bio-medicine Co., Ltd operates as a biomedical technology company. It operates in two segments, Biomedicine, and Energy Saving and Environmental Protection. The Biomedicine segment provides stem cell and immune cell testing, storage, and technical services; as well as sales of biopharmaceutical products, such as beauty products, health supplements, and air purifiers. The Energy Saving and Environmental Protection segment is involved in the external energy management contract energy management business; build-transfer business and sales of related products; and sewage treatment business. The company was incorporated in 1991 and is headquartered in Changsha, China.
Nanhua Bio Medicine Co Ltd management
5- Mr. Yun YangGM & Chairman · born 1980
- Mr. Pengbin LinDeputy GM & CFO · born 1973
- Ms. Yi ChenAccounting Supervisor & Employee Representative Director · born 1983
- Mr. Liang SuDeputy GM & Secretary of the Board · born 1980
- Mr. Ailong LiuDeputy General Manager · born 1978